The emergence of novel immunotherapeutic approaches for the treatment of
cancer produced a revolution in oncology during past decade. Check-point inhibitors
were shown to be active against the wide range of malignancies and most significantly
to be able to generate long-lasting responses and probably cure in some patients with advanced disease. These data inspired hope in cancer patients and physicians for the victory in the war against cancer in
the near future. However it appeared clear that immunotherapy is not a panacea and is active only in a subset of cancer patients. Moreover in some settings immunotherapy shows inferior results compared to standard chemotherapy and possibly can even make harm. In this paper the positive and negative features of immunotherapeutic approaches for cancer treatment are overviewed. Also hypothetical limits of immunotherapy effectiveness in the future and the current place in cancer treatment practice
are discussed.